🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06644794
Recruiting Phase 3

Progesterone-modified Natural Cycle for FET

NCT06644794 · tracked via the Priya Life Science China tracker
Sponsor
Shandong University of Traditional Chinese Medicine
Phase
Phase 3
Started
2025-03-05
Last updated
2026-04-29

Condition(s) studied

Infertility, Female

Investigational drug(s) / intervention(s)

Progesterone-modified natural cycle preparation for frozen embryo transferHormone replacement therapy cycle preparation for frozen embryo transfer

Progesterone-modified natural cycle preparation for frozen embryo transfer: A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.

Hormone replacement therapy cycle preparation for frozen embryo transfer: A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.

Study summary

Hormone replacement therapy (HRT) cycles, despite the ease of synchronizing embryo thawing and embryo transfer timing, increase the risk of pregnancies and obstetric complications compared to natural cycles (NC). By ensuring the presence of the corpus luteum while reducing the number of monitoring sessions, the progesterone modified natural cycle (P4mNC) offers more convenience for the patient than the normal NC. This study is designed to compare the effects of P4mNC and HRT cycles on FET outcomes.

Eligibility

Sex
FEMALE
Min age
21 Years
Max age
44 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 21 to 44 years undergoing FBT * Body mass index (BMI) 18-35 kg/m2 * Having regular ovulatory cycles Exclusion Criteria: * Untreated uterine adhesions * Medical contraindications to estrogen and progesterone therapy * Illnesses contraindicating assisted reproductive technology or pregnancy * History of recurrent implantation failures (\> 2 embryo transfer failures)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Affiliated Hospital of Shandong University of Traditional Chinese Medicine Jinan Shandong Recruiting

More Shandong University of Traditional Chinese Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06644794 on ClinicalTrials.gov ↗ ← All trials in China